Allurion initiated with a Buy at TD Cowen ahead of ‘potentially major’ catalyst

As previously reported, TD Cowen analyst Joshua Jennings initiated coverage of Allurion Technologies with a Buy rating and $2 price target Allurion targets the large, high-growth global obesity market with its intragastric balloon, which does not require anesthesia or endoscopy, drives durable weight loss and is significantly safer than earlier-gen devices, the analyst tells investors. The firm views the year-end readout of the U.S. Audacity trial as a “potentially major positive catalyst for the stock,” the analyst added.